Inflammation-associated drug resistance and tumor growth in TNBC

Inflammation-associated drug resistance and tumor growth in TNBC

Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of hormone receptors and HER2 amplification. This molecular profile limits the effectiveness of targeted therapies, leaving chemotherapy as the mainstay of treatment...

Full description

Saved in:

Bibliographic Details
Main Authors:	Arij Fouzat Hassan, Hadeel Kheraldine, Lama Abujamous, Hamda Al-Thawadi, Abdelbary Elhissi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	triple-negative breast cancer (TNBC) tumor microenvironment (TME) inflammation cytokines drug resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623137/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Synergistic inhibition of TNBC by USP33 and TAP63 through autophagy and ferroptosis activation
by: Feilin Qu, et al.
Published: (2025-08-01)

Mechanistic exploration of Traditional Chinese Medicine regulation on tumor immune microenvironment in the treatment of triple-negative breast cancer: based on CiteSpace and bioinformatics analysis
by: Dandan Feng, et al.
Published: (2025-01-01)

Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)
by: Khashayar Yazdanpanah Ardakani, et al.
Published: (2025-07-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Plant metabolites and functional foods in metastatic breast cancer: a supportive strategy for management
by: Pritya Jha, et al.
Published: (2025-07-01)

Characterization of Disseminated Tumor Cells (DTCs) in Patients with Triple-Negative Breast Cancer (TNBC)
by: Anne Eckardt, et al.
Published: (2025-06-01)

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
by: Huayan Gu, et al.
Published: (2025-02-01)

Knowledge mapping of ultrasound technology and triple-negative breast cancer: a visual and bibliometric analysis
by: Yonglin Wan, et al.
Published: (2025-07-01)

Machine learning identifies SRD5A3 as a propionate-related prognostic biomarker in triple-negative breast cancer
by: Kelun Pan, et al.
Published: (2025-05-01)

GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2
by: Qingyi Hu, et al.
Published: (2025-07-01)

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms
by: Nicholas L. Calistri, et al.
Published: (2025-02-01)

The search for a TNBC vaccine: the guardian vaccine
by: Cory Fines, et al.
Published: (2025-12-01)

Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
by: Mingyao Huang, et al.
Published: (2025-05-01)

Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature
by: Mojtaba Esmaeli, et al.
Published: (2025-04-01)

The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
by: Lijuan Weng, et al.
Published: (2024-03-01)

MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer
by: Cheng Hyun Lee, et al.
Published: (2025-07-01)

Comprehensive analysis of metabolism-related gene biomarkers reveals their impact on the diagnosis and prognosis of triple-negative breast cancer
by: Weibin Ren, et al.
Published: (2025-04-01)

The Role of Genomics and Transcriptomics in Characterizing and Predicting Patient Response to Treatment in Triple Negative Breast Cancer (TNBC)
by: Franklin Eduardo Corea-Dilbert, et al.
Published: (2025-04-01)

The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge
by: Marianna Rita Brogna, et al.
Published: (2025-03-01)

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
by: Rebecca Dent, et al.
Published: (2025-03-01)

The integrated single-cell analysis interpret the lactate metabolism-driven immune suppression in triple-negative breast cancer
by: Xinhai Gao, et al.
Published: (2025-05-01)

Molecular Mechanisms of <i>Lobelia nummularia</i> Extract in Breast Cancer: Targeting EGFR/TP53 and PI3K-AKT-mTOR Signaling via ROS-Mediated Apoptosis
by: Fahu Yuan, et al.
Published: (2025-07-01)

Molecular genetic predictors of progression of triple negative breast cancer
by: I. S. Panchenko, et al.
Published: (2025-03-01)

In silico design and in vitro validation of a multi-epitope peptide vaccine targeting triple-negative breast cancer
by: Pengjun Zhou, et al.
Published: (2025-06-01)

The circDUSP1/miR-429/DLC1 regulatory network affects proliferation, migration, and invasion of triple-negative breast cancer cells
by: Canhui Jian, et al.
Published: (2025-07-01)

Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
by: Zaid Sirhan, et al.
Published: (2025-04-01)

Echinochrome A inhibits epithelial–mesenchymal transition and induces cell death mediated by DNA damage in human triple-negative breast cancer cells
by: Soon Yong Park, et al.
Published: (2025-10-01)

Androgen receptor expression in triple negative breast cancer: an Algerian population study
by: Amel Hedjem, et al.
Published: (2025-12-01)

Single-cell and transcriptome analyses revealed CTHRC1 a potential therapeutic target mediating invasion and tumor microenvironment in TNBC: experimental validation
by: Hong Wan, et al.
Published: (2025-03-01)

Discovery and biological evaluation of a novel and highly potent JAK2 inhibitor for the treatment of triple negative breast cancer
by: Yingxiang Miao, et al.
Published: (2025-12-01)

Pentagalloyl Glucose from <i>Bouea macrophylla</i> Suppresses the Epithelial–Mesenchymal Transition and Synergizes the Doxorubicin-Induced Anticancer and Anti-Migration Effects in Triple-Negative Breast Cancer
by: Jiraporn Kantapan, et al.
Published: (2024-12-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes
by: Betul Celik Demirbas, et al.
Published: (2025-05-01)

miRNA-REGULATED PATHWAYS OF CD8+ T CELLS IN TNBC MOUSE MODEL
by: Müge Öçal Demirtaş, et al.
Published: (2022-08-01)

Pristimerin Promotes Ubiquitination of HSPA8 and Activates the VAV1/ERK Pathway to Suppress TNBC Proliferation
by: Qin‐Wen Liu, et al.
Published: (2025-03-01)

NRF3 suppresses the malignant progression of TNBC by promoting M1 polarization of macrophages via ROS/HMGB1 axis
by: Ping Xing, et al.
Published: (2024-12-01)

The value of inflammation-related indicators in chemotherapy efficacy and disease-free survival of triple-negative breast cancer
by: Jie Zhu, et al.
Published: (2025-02-01)

Novel Thymoquinone Derivative TQFL28 Inhibits Triple-Negative Breast Cancer (TNBC) Invasiveness In Vitro and In Vivo
by: Jiayue He, et al.
Published: (2025-06-01)

A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression
by: Xiaohan Su, et al.
Published: (2025-04-01)

The novel amino-artemisinin derivative WHN-11 disrupts mitochondria and protein homeostasis, and induces autophagy and apoptosis in cancer cells
by: Deborah Kajewole, et al.
Published: (2025-07-01)